{"id":"W3088603564","doi":"10.1016/j.annonc.2020.08.429","title":"327P Treatment sequencing in HR+/HER2- locally advanced or metastatic breast cancer: A real-world retrospective study in France, Germany, Italy and Spain","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Pfizer Pharmaceuticals; Novartis Pharmaceuticals Canada; Celldex Therapeutics; Astellas Pharma; Eisai; Chugai Pharmaceutical; Celltrion; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Celltrion Healthcare; Daiichi-Sankyo; Pfizer; Genomic Health","keywords":"Medicine; Fulvestrant; Internal medicine; Breast cancer; Metastatic breast cancer; Oncology; Cancer; Clinical trial; First line treatment; Chemotherapy; Tamoxifen","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001257908,0.0003240705,0.0005854889,0.0008685329,0.0002979772,0.001218893,0.0004402355,0.0005736784,0.001425821],"category_scores_gemma":[0.002118885,0.0002577362,0.000518822,0.001277762,0.0004142841,0.0002627404,0.0005707366,0.0003368592,0.0002343811],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001837197,"about_ca_system_score_gemma":0.0009429249,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02751787,"about_ca_topic_score_gemma":0.02368552,"domain_scores_codex":[0.9992037,0.0002276574,0.00006291881,0.0002262015,0.0001077245,0.0001718594],"domain_scores_gemma":[0.9988855,0.0002555388,0.0004088869,0.0001124779,0.0001966066,0.0001410623],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00082401,0.00005038968,0.9898071,0.00006865351,0.0003210049,0.0005460316,0.0002518984,0.0004142057,0.0004347475,0.0001279914,0.000920031,0.006234016],"study_design_scores_gemma":[0.0000636945,0.0001460865,0.9947219,0.00005600675,0.000172339,0.0008416405,0.0006777697,0.0002754484,0.0001123271,0.000049739,0.002872519,0.00001054358],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964793,0.00110429,0.0001303856,0.0001157914,0.00001231387,0.000009784126,0.001340955,0.00000653991,0.0008006698],"genre_scores_gemma":[0.9971583,0.0004936869,0.0001099608,0.0001935906,0.00001482149,0.00001292981,0.001732684,0.00001249286,0.0002714742],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02751787,"threshold_uncertainty_score":0.05471545,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07734766725541938,"score_gpt":0.4071170968901116,"score_spread":0.3297694296346922,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}